Document is current
Any future updates will be listed below
-
Authors
LaFata, Sean S.
Redd, Walker D.
Aleman, Stefani
Weir, Alexandra A.
Gee, Timothy S.
Lackey, Angelica R.
Juneja, Arjun K.
Thel, Hannah L.
Cameron, Brenderia A.
McCallen, Justin
Lee, Christopher J.
Hendrick, Gustaf N.
Bermudez, Jose C.
Song, Daniel
Barlowe, Trevor S.
Cotton, Cary C.
Reed, Craig C.
Dellon, Evan S.
-
Funding
Funding for this research was provided by:
NIH (T35 DK007386)
NIH (T32 DK007634)
- License Information
-
More Information
Article History
Received: 30 July 2025
Accepted: 26 December 2025
First Online: 4 January 2026
Declarations
:
: Dr. Dellon is a consultant for Abbott, Abbvie, Adare/Ellodi, Aimmune, Akesobio, Alfasigma, ALK, Allakos, Amgen, Apogee, Apollo, Aqilion, Arena/Pfizer, Aslan, AstraZeneca, Avir, Biorasi, Bryn, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, Eupraxia, Dr. Falk Pharma, Ferring, GSK, Gossamer Bio, Holoclara, Invea, Knightpoint, Landos, LucidDx, Morphic, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda, Target RWE, Third Harmonic Bio, Upstream Bio; receives research funding from Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Celldex, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, Shire/Takeda; and has received an educational grant from Allakos, Aqilion, Holoclara, Invea. Dr. Redd is a consultant for Sanofi. None of the other authors report any potential conflicts of interest with this study.
